Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease (Q34570343)

3 August 2017

1 reference

title

Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease (English)

1 reference

3 August 2017

Mark D DeBoer

1

1 reference

3 August 2017

Daniel L Marks

series ordinal

2

1 reference

3 August 2017

publication date

1 August 2006

1 reference

Nature Clinical Practice Endocrinology and Metabolism

3 August 2017

published in

1 reference

3 August 2017

volume

2

1 reference

3 August 2017

issue

8

1 reference

3 August 2017

page(s)

459-466

1 reference

Hormonal Changes and Catabolic/Anabolic Imbalance in Chronic Heart Failure and Their Importance for Cardiac Cachexia

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

Peripheral endotoxin induces hypothalamic immunoreactive interleukin-1 beta in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Binge Eating as a Phenotype of Melanocortin 4 Receptor Gene Mutations

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

The Sir David Cuthbertson Medal Lecture 1991. The mechanisms and treatment of weight loss in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Factors predicting malnutrition in hemodialysis patients: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Quality of life and survival prediction in terminal cancer patients: a multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Wasting as independent risk factor for mortality in chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Resting Energy Expenditure and Subsequent Mortality Risk in Peritoneal Dialysis Patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Cachexia in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Systemic inflammation, cachexia and prognosis in patients with cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Mechanisms of hypoalbuminemia in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Anatomy and regulation of the central melanocortin system

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

A homozygous null mutation delineates the role of the melanocortin-4 receptor in humans.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Brain somatic cross-talk: ghrelin, leptin and ultimate challengers of obesity

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Gut hormone PYY(3-36) physiologically inhibits food intake

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Effect of LPS administration on the expression of POMC, NPY, galanin, CART and MCH mRNAs in the rat hypothalamus

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Role of leptin and melanocortin signaling in uremia-associated cachexia

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Responsiveness to peripherally administered melanocortins in lean and obese mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Cachexia: time to receive more attention

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Reversal of cancer anorexia by blockade of central melanocortin receptors in rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Differential role of melanocortin receptor subtypes in cachexia

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0221

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0221

1 reference

3 August 2017

1 reference